Trial Profile
Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs CAT 3888 (Primary)
- Indications Hairy cell leukaemia
- Focus Therapeutic Use
- 30 Apr 2012 Actual patient number 1 added as reported by ClinicalTrials.gov.
- 30 Apr 2012 Actual patient number 1 added as reported by ClinicalTrials.gov.
- 30 Apr 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.